IFNG and T-cell non-Hodgkin lymphoma: Tokunaga, R., et al. has found that EBV miR-BART20-5p directly targets the inhibition of T-bet expression in invasive EBV+ nasal NK/T-cell lymphoma, and EBV miR-BART8 can indirectly block IFN-γ/STAT1 pathway, can inhibit IFN-γ activation of the immune response.